Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

About this update from Alnylam Pharmaceuticals, Inc.

Expanded agreement extends Marmot across key enterprise functions, advancing a new operating model for AI-powered decision-making in Life Sciences Komodo also unveils new Marmot capabilities to move organizations beyond AI experimentation and into enterprise-wide intelligence NEW YORK & SAN FRANCISCO, June 25, 2026 --( BUSINESS WIRE )--Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo's analytics AI platform, across key enterprise functions at Alnylam. Built on the Healthcare Map®, the industry's most comprehensive view of more than 330 million de-identified patient journeys, Marmot helps organizations move beyond fragmented analytics and static reporting toward real-time, transparent, and reproducible healthcare intelligence. Launched in August 2025, Alnylam was an early adopter of the platform, with the collaboration initially focused on building custom AI agents for Alnylam's commercial business function. The expanded partnership will enable Alnylam to deploy Marmot across its customer-facing organization and leverage its capabilities more broadly across the enterprise, creating a unified foundation for data-driven decision-making at scale. "Alnylam's ability to create meaningful impact is built on breakthrough science, strong execution, and an unwavering commitment to patients," said Tolga Tanguler, Chief Commercial Officer at Alnylam. "This new capability strengthens our ability to connect insight into action, helping us scale more effectively, accelerate decision-making, and continue delivering sustainable growth while maintaining our focus on patients." Since initially deploying Marmot, Alnylam and Komodo have built and deployed custom AI agents across critical workflows. Alnylam has integrated a wide range of enterprise datasets into the platform, transforming how teams access and act on insights by eliminating reliance on fragmented dashboards, reducing reporting cycles from months to hours, and enabling teams to generate insights that were previously out of reach. Marmot will continue to support Alnylam as the company works toward a range of operational and patient impact objectives. Advancing the Next Generation of Enterprise Healthcare AI The expanded partnership reflects a broader shift occurring across healthcare and Life Sciences as organizations move beyond AI experimentation and begin adopting new operating models built around real-time intelligence. As the limitations of disconnected dashboards, static reporting, and siloed analytics become increasingly apparent, the focus is turning toward enterprise-wide systems that can continuously generate, distribute, and operationalize trusted, verifiable insights across teams.

View stock analysis, news, and events for Alnylam Pharmaceuticals, Inc.